不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD20 CAR 工程化改造的新转折
英文原题：Engineering CD20 CARs with a Twist.
查看英文原题
Engineering CD20 CARs with a Twist.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD20在多种B细胞淋巴瘤中高表达，是嵌合抗原受体（CAR）T细胞疗法的直观靶点。然而，采用传统方法设计的CD20 CAR难以在临床前模型和临床试验中产生理想疗效。本期中，Chen及其同事报告了若干改良型CD20 CAR；这些设计仅对传统设计原则作了有限调整，却在临床前模型中实现了可治愈淋巴瘤的疗效。这些新型CD20 CAR丰富了临床开发候选方案，也展示了如何依据对CAR结构域结构生物学的认识进行理性设计。相关研究见Chen等人发表于第150页（第3篇）的文章。
展开英文摘要原文
CD20 is highly expressed in several types of B-cell lymphoma and is an intuitive target for chimeric antigen receptor (CAR) T-cell therapy.
However, with conventional approaches, it has been challenging to provide CD20 CAR designs that confer efficacy in preclinical models and in clinical trials. In this issue, Chen and colleagues report several improved CD20 CARs, developed with minimal deviations from conventional design principles, that confer curative anti-lymphoma efficacy in preclinical models.
These novel CD20 CARs enrich the pipeline for clinical development and provide an example of rational CAR design that is informed by insights into the structural biology of CAR domains. See related article by Chen et al. , p. 150 (3).
论文信息
- 作者
- Scheller L、Hudecek M
- 单位
- Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.Germany
- 文献类型
- 评论
- 期刊
- Cancer immunology research2023 Feb 3
- 原文标识
- PubMed 36633575 · DOI 10.1158/2326-6066.CIR-22-0919